Rapid anti-inflammatory action of azelastine eyedrops for ongoing allergic reactions

Annals of Allergy, Asthma and Immunology

Volumn 90, Issue 4, 2003, Pages 434-438

  Ciprandi, Giorgio ^a,b   Cosentino, Cristina ^a   Milanese, Manlio ^a   Tosca, Maria Angela ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZELASTINE; INTERCELLULAR ADHESION MOLECULE 1; PLACEBO;

ADULT; ALLERGIC REACTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BITTER TASTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVA EPITHELIUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EOSINOPHIL; EYELID EDEMA; FEMALE; HUMAN; HYPEREMIA; INFLAMMATORY CELL; LACRIMATION; LYMPHOCYTE; MALE; MONOCYTE; NEUTROPHIL; POLLEN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037393734     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61829-7     Document Type: Article

References (27)

1. Walsh GM, Annunziato L, Frossard N, et al. New insights into the second generation antihistamines. Drugs 2001;61:207-236.
2. 1-antihistamines and inflammation. Clin Exp Allergy 2001;31:1341-1343.
3. Hayashi S, Hashimoto S. Anti-inflammatory actions of new antihistamines. Clin Exp Allergy 1999;29:1593-1596.
4. McTavish D, Sorkin EM. Azelastine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1984;38:778-800.
5. Ciprandi G, Buscaglia S, Pesce G, et al. Allergic subjects express intercellular adhesion molecule-1 (ICAM-1 or CD54) on epithelial cells of conjunctiva after allergen challenge. J Allergy Clin Immunol 1993;91:783-792.
6. Ciprandi G, Buscaglia S, Pesce GP, et al. ICAM-1/CD54 expression on conjunctival epithelium during pollen season. Allergy 1995;50:184-187.
7. Ciprandi G, Tosca MA, Fasce L, Canonica GW. Allergen-specific conjunctival challenge in children with allergic asthma: a clinical tool. Allergy 1994;49:489-491.
8. Chand N, Pillar J, Diamantis W, Sofia RD. Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs. Agents Actions 1985;16:318-322.
9. Fields DA, Pillar J, Diamantis W, et al. Inhibition by azelastine of nonallergic histamine release from rat peritoneal mast cells. J Allergy Clin Immunol 1984;73:400-403.
10. Fischer B, Schmutzler W. Inhibition by azelastine of the immunologically induced histamine release from isolated guinea pig mast cells. Arzneimittelforschung 1981;31:1193-1195.
11. Katayama S, Tsunoda H, Sakuma Y, et al. Effect of azelastine on the release and action of leukotriene C4 and D4. Int Arch Allergy Appl Immunol 1987;83:284-289.
12. Shin MH, Baroody F, Proud D, et al. The effect of azelastine on the early allergic response. Clin Exp Allergy 1992;22:289-295.
13. Baggiolini M, Dahinden CA. CC chemokines in allergic inflammation. Immunol Today 1994;15:127-133.
14. Ciprandi G, Pronzato C, Ricca V, et al. Allergen-specific challenge induces intracellular adhesion molecule 1 (ICAM-1 or CD54) on nasal epithelial cells in allergic subjects. Relationships with early and late inflammatory phenomena. Am J Respir Crit Care Med 1994;150:1653-1659.
15. Canonica GW, Ciprandi G, Buscaglia S, et al. Adhesion molecules of allergic inflammation: recent insights into their functional roles. Allergy 1994;49:135-141.
16. Arnold R, Rihoux J, Konig W. Cetirizine counter-regulates interleukin-8 release from human epithelial cells (A549). Clin Exp Allergy 1999;29:1681-1691.
17. 1-antihistamine in asthma. Int Arch Allergy Immunol 1999;118:380-383.
18. Yoneda K, Yamamoto T, Ueta E, Osaki T. Suppression by azelastine hydrochloride of NF-κB activation involved in generation of cytokines and nitric oxide. Jpn J Pharmacol 1997;73:145-153.
19. Ciprandi G, Buscaglia S, Catrullo A, et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin Exp Allergy 1997;27:182-191.
20. Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995;95:612-621.
21. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-142.
22. Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 2001;23:1272-1280.
23. Duarte C, Baehre M, Gharakhanian S, Leynadier F. Treatment of severe seasonal rhinoconjunctivitis by a combination of azelastine nasal spray and eye drops: a double-blind, double-placebo study. J Investig Allergol Clin Immunol 2001;11:34-40.
24. Giede C, Metzenauer P, Petzold U, Ellers-Lenz B. Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis. Curr Med Res Opin 2000;16:153-163.
25. Friedlaender MH, Harris J, LaVallee N, et al. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model. Ophthalmology 2000;107:2152-2157.
26. Giede-Tuch C, Westhoff M, Zarth A. Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis: a double-blind, randomized, placebo-controlled study. Allergy 1998;53:857-862.
27. Sabbah A, Marzetto M. Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children. Curr Med Res Opin 1998;14:161-170.